6.94
Xeris Biopharma Holdings Inc Aktie (XERS) Neueste Nachrichten
Barclays Initiates Coverage on Xeris Biopharma Holdings (XERS) w - GuruFocus
Xeris Biopharma’s (XERS) Positioning Strengthens After Reaching Product Pipeline Milestone - Insider Monkey
7 Hidden Multibagger Stocks to Invest In - Insider Monkey
Xeris Biopharma Holdings (XERS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Xeris Biopharma (XERS) Is Down 9.3% After XP-8121 Patent Milestone Is Announced – Has The Bull Case Changed? - Yahoo Finance
How Xeris Biopharma Holdings Inc. stock performs in weak economy2025 Price Momentum & Verified Trade Idea Suggestions - Newser
Why Xeris Biopharma Holdings Inc. (2B30) stock is favored by hedge funds2025 Momentum Check & Fast Gain Stock Tips - Newser
What Wall Street predicts for Xeris Biopharma Holdings Inc. stock price2025 Major Catalysts & Verified High Yield Trade Plans - Newser
How higher bond yields impact Xeris Biopharma Holdings Inc. (2B30) stockJuly 2025 Opening Moves & Community Verified Watchlist Alerts - Newser
Xeris Biopharma (NASDAQ:XERS) Insider Sells $116,835.67 in Stock - MarketBeat
Xeris Biopharma (NASDAQ:XERS) Shares Down 4.9%Here's Why - MarketBeat
What Analysts Think Is Changing The Story For Xeris Biopharma Holdings - Yahoo Finance
What is Xeris Biopharma Holdings Inc (XERS) Stock Return on Shareholders’ Capital? - Setenews
Risks Still Elevated At These Prices As Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Dive 35% - simplywall.st
Legal & General Group Plc Purchases 392,589 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Is Xeris Biopharma Holdings Inc. stock a safe buy before earningsEarnings Growth Summary & Safe Capital Growth Plans - Newser
Why Xeris Biopharma Holdings Inc. (2B30) stock appeals to dividend investorsMarket Risk Analysis & Growth Focused Entry Reports - Newser
Hecht Beth, Xeris Biopharma chief legal officer, sells $116k in XERS - Investing.com India
Hecht Beth, Xeris Biopharma chief legal officer, sells $116k in XERS By Investing.com - Investing.com South Africa
Xeris Biopharma Holdings Director Beth Hecht Sells Shares - TradingView
Officer Hecht Sells 16,667 ($116.8K) Of Xeris Biopharma Holdings Inc [XERS] - TradingView
Oversold Conditions For Xeris Biopharma Holdings (XERS) - Nasdaq
Why Xeris Biopharma Holdings Inc. (2B30) stock is listed among top recommendations2025 Institutional Moves & Daily Stock Momentum Reports - Newser
A Look at Xeris Biopharma (XERS) Valuation After Patent Progress on Novel Hypothyroidism Therapy - Sahm
Xeris Pharmaceuticals Secures Patent Allowance for XP-8121 - MSN
Xeris Biopharma receives patent allowance for hypothyroidism drug By Investing.com - Investing.com Australia
Is Xeris Biopharma Holdings Inc 2B30 a good long term investmentPrice Action Analysis & Small Investment Growth Tips - earlytimes.in
Xeris Biopharma Receives Notice of Allowance for XP-8121 Patent - marketscreener.com
Xeris BioPharma Holdings Incunit receives USPTO notice of allowance for XP-8121 patent - marketscreener.com
Xeris Biopharma (XERS) Advances with New Patent Approval - GuruFocus
Xeris Biopharma receives patent allowance for hypothyroidism drug - Investing.com
Xeris Biopharma Holdings, Inc. Receives Notice of Allowance for XP-8121 Patent - TradingView
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application - marketscreener.com
Xeris Biopharma (Nasdaq: XERS) receives USPTO Notice of Allowance for XP-8121 - Stock Titan
Prudential Financial Inc. Buys 457,784 Shares of Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Intech Investment Management LLC Has $441,000 Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Geode Capital Management LLC Boosts Stock Position in Xeris Biopharma Holdings, Inc. $XERS - MarketBeat
Adversity is less terrifying than hope: Xeris Biopharma Holdings Inc (XERS) - Setenews
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Xeris Biopharma Holdings, Inc. $XERS Shares Acquired by CenterBook Partners LP - MarketBeat
What drives Xeris Biopharma Holdings Inc 2B30 stock priceDividend Stability Analysis & Stay Safe With Built-In Risk Monitoring - earlytimes.in
Xeris Biopharma Faces Weak Start with 15% Gap Down Amid Market Concerns - Markets Mojo
Will Xeris Biopharma Holdings Inc. (2B30) stock hit Wall Street targetsPortfolio Value Summary & Low Drawdown Investment Ideas - newser.com
Xeris Biopharma Holdings (XERS) Price Target Increased by 27.78% to 11.73 - MSN
Will Xeris Biopharma Holdings Inc. stock deliver long term returns2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Detecting support and resistance levels for Xeris Biopharma Holdings Inc.2025 Year in Review & Verified Stock Trade Ideas - newser.com
Leerink Partnrs Forecasts Xeris Biopharma FY2025 Earnings - Defense World
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):